๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Baotou, Beijing, Guangzhou, Shenzhen
2025-09-19
Active, closed
AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia
NCT07461714Severe Pneumonia
Guangzhou Medical University
Observational
1,000
Guangzhou
2025-09-18
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
NCT07192185Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-17
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-09-17
Recruiting
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
NCT07215650Generalized Myasthenia Gravis
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Fuzhou, Guangzhou, Beijing, Xi'an
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Not yet open
A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.
NCT07141147Radiotherapy, High-risk Localized Adrenocortical Carcinoma
Sun Yat-sen University
Not applicable
58
Guangzhou
2025-09-15
Recruiting
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT07077512Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-15
Recruiting
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
NCT07088263Breast Neoplasms
Sun Yat-sen University
Phase 3
192
Guangzhou
2025-09-15
Not yet open
Episodic Future Thinking to Improve Anticoagulant Adherence in Atrial Fibrillation
NCT07174778Atrial Fibrillation (AF)
Jiawen You
Not applicable
68
Guangzhou
2025-09-15
Not yet open
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
NCT07174375Acute Ischemic Stroke
Nanfang Hospital, Southern Medical University
Phase 2/3
478
Fuzhou, Dongguan, Guangzhou, Heyuan, Hengzhou, Haikou, Ganzhou
2025-09-15
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
NCT07084662Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2/3
80
Guangzhou
2025-09-11
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07174908Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Not yet open
CVL006 Combination Therapy in Advanced Solid Tumors
NCT07157956Advanced Solid Tumor
Convalife (Shanghai) Co., Ltd.
Phase 1/2
318
Guangzhou
2025-09-10
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Recruiting
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
NCT07177794Esophageal Cancer, Chemoradiotherapy
Sun Yat-sen University
Phase 3
242
Guangzhou
2025-09-10
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
Efficacy Evaluation of 5-Fluorouracil as an Adjuvant to Endoscopic Dacryocystorhinostomy in Managing Primary Acquired Nasolacrimal Duct Obstruction With Small Lacrimal Sac: A Randomized Controlled Study
NCT07154121Primary Acquired Nasolacrimal Duct Obstruction
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
100
Guangzhou
2025-09-08
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Recruiting
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
200
Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan, Shanghai
2025-09-05
Not yet open
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
NCT07158840Non-Small Cell Lung Cancer
Akeso
Phase 2
60
Guangzhou
2025-09-05
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554Chronic Obstructive Pulmonary Disease (COPD)
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT07137910Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Recruiting
The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
NCT07156773Parkinson Disease
Guangzhou Novaken Pharm Co., Ltd.
Phase 2
84
Guangzhou
2025-09-03
Recruiting
Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study
NCT07542171Early Colorectal Cancer, Non-curative Endoscopic Resection
Nanfang Hospital, Southern Medical University
Observational
400
Guangzhou, Shenzhen, Haizhu
2025-09-03
Recruiting
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
NCT07098403Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 3
408
Guangzhou
2025-09-03
Active, closed
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNฮฑ for the Treatment of Hepatitis B
NCT07135349Chronic Hepatitis B
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
209
Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi
2025-09-02
Recruiting
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NCT07093814Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1/2
42
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan
2025-09-02
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong
2025-09-02
Not yet open
Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment
NCT06773117Cough
Tasly Pharmaceutical Group Co., Ltd
Phase 3
360
Hefei, Chongqing, Guangzhou, Zunyi, Xingtai, Kaifeng, Nanyang, Sanmenxia
2025-09-01
Not yet open
A Randomized Controlled Study on the Improvement of Medical Experience for Patients With Radiation-induced Oropharyngeal Mucositis Based on the RIS System of the Internet of Things
NCT07126457Head and Neck Cancer, Radiation-Induced Mucositis
Nanfang Hospital, Southern Medical University
Not applicable
110
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09-01
Active, closed
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
NCT07060885Allergic Rhinoconjunctivitis, Allergic Rhinitis
ALK-Abellรณ A/S
Phase 3
327
Beijing, Fuzhou, Guangzhou, Shenzhen, Zhuhai, Nanning, Haikou, Changshacun
2025-09-01
Recruiting
Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction
NCT07263711Glioma
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou
2025-09-01
Recruiting
Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies
NCT07058454Cancer;Cardiovascular;Adverse Events, Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
5,000
Guangzhou
2025-09-01
Recruiting
Diagnostic Trial of a Vision Transformer-Based Ultrasound AI Model for Placenta Accreta Spectrum
NCT07643090Placenta Accreta Spectrum
FANG HE
Observational
561
Guangzhou
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Not yet open
Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
NCT07156656Type A Aortic Dissection, Organ Failure, Multiple
Shanghai Zhongshan Hospital
Phase 4
236
Hefei, Fuzhou, Guangzhou, Shenzhen, Xi'an, Shanghai
2025-09-01
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
NCT07119918Symptomatic Intracranial Atherosclerotic Stenosis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
5,276
Guangzhou
2025-09-01
Recruiting
We-INtervention Among Chinese HIV-serodiscordant Male Couples
NCT06639932HIV
City University of Hong Kong
Not applicable
320
Xiamen, Guangzhou, Shenzhen, Chengdu
2025-09-01
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Recruiting
Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients
NCT07377279Breast Cancer, Chemotherapy-induced Peripheral Neuropathy (CIPN)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
384
Guangzhou
2025-09-01
Not yet open
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
NCT07040644Triple Negative Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
150
Guangzhou
2025-09
Recruiting
Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis
NCT06307327Head and Neck Cancer, Radiation-Induced Mucositis
Nanfang Hospital, Southern Medical University
Observational
264
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09
Recruiting
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499NSCLC, Adjuvant Drug Therapy, EGFR
Betta Pharmaceuticals Co., Ltd.
Phase 2
28
Guangzhou, Zhuhai
2025-09
Not yet open
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
NCT07131150Idiopathic Pulmonary Fibrosis (IPF)
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Not yet open
HS-IT101 Injection for Advanced NSCLC
NCT07105176Advanced Non-Small Cell Lung Cancer
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 1
12
Guangzhou
2025-08-30
Recruiting
Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial
NCT07230639Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
52
Guangzhou
2025-08-30
Recruiting
The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Children
NCT07168720Preoperative Sedation
Guangzhou Novaken Pharm Co., Ltd.
Phase 2
64
Guangzhou
2025-08-29
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
Prospective Pathology Foundation Models
NCT07157618Pancancer
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Jinan
2025-08-28
Recruiting
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT07146100Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Observational
200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-28
Not yet open
A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
NCT07126171Chikungunya Fever
Jiangsu Kanion Pharmaceutical Co., Ltd
Not applicable
400
Guangzhou
2025-08-28
Recruiting
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NCT07093710Peripheral T Cell Lymphoma
Sun Yat-sen University
Phase 1/2
101
Guangzhou
2025-08-27
Not yet open
Effect of Light-Blocking Lenses on Pediatric Hyperopia
NCT07142915Hyperopia
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
156
Guangzhou
2025-08-25
Recruiting
Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients
NCT07126470Cataract, Retinitis Pigmentosa (RP)
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
88
Guangzhou, Shenzhen, Wuhan
2025-08-25
Active, closed
Milk Free From A1-Type ฮฒ-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes
NCT06980376Healthy Pregnant Women
a2 Milk Company Ltd.
Not applicable
100
Foshan, Guangzhou, Wuxi, Xuzhou, Chengdu
2025-08-25
Not yet open
Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children
NCT07142928Anisometropia, Hyperopia
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
90
Guangzhou
2025-08-25
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Beijing, Beijin, Guangzhou, Wuhan, Xi'an
2025-08-21
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC
Phase 2/3
153
Beijing, Guangzhou, Shanghai, Hangzhou
2025-08-21
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
Phase 3
180
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang
2025-08-21
Not yet open
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07138989Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
10
Guangzhou
2025-08-19
Recruiting
Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
NCT07011524Asthma
Keymed Biosciences Co.Ltd
Phase 2
200
Guangzhou
2025-08-19
Recruiting
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT07133750CRC (Colorectal Cancer)
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650Diffuse Large B-Cell Lymphoma
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
NCT07037199Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
45
Guangzhou
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Recruiting
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023Breast Cancers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
112
Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen
2025-08-15
Not yet open
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
NCT07110558Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
59
Guangzhou
2025-08-15
Recruiting
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
NCT07158710Malignant Brain Tumors
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
159
Beijing, Fuzhou, Guangzhou, Changchun, Shanghai
2025-08-15
Recruiting
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)
Sun Yat-sen University
Phase 3
386
Guangzhou, Guilin, Sanya, Changsha, Nanjing
2025-08-15
By invitation
A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data
NCT07532928Deep Learning, Head & Neck Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
Observational
571
Guangzhou
2025-08-15
Recruiting
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
NCT07092709Acute Ischemic Stroke
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
912
Guangzhou
2025-08-14
By invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629TNBC
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Active, closed
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC
NCT07703228NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, Second-line Therapy, Metastases
Nanfang Hospital, Southern Medical University
Phase 2
38
Guangzhou
2025-08-13
Recruiting
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
NCT06947967Lymphoma, T-Cell, Peripheral
Chipscreen Biosciences, Ltd.
Phase 3
224
Guangzhou
2025-08-12
Recruiting
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
NCT06896708Chronic Coronary Syndrome
Liu yong
Not applicable
766
Chongqing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Dalian
2025-08-12
Active, closed
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
NCT07246889Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Recruiting
A Study of HDM2020 in Patients With Advanced Solid Tumors
NCT07098052Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
60
Guangzhou
2025-08-11
Recruiting
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947Atopic Dermatitis
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
Effects of Acute Sleep Deprivation on Individuals With Different APOE Genotypes
NCT07085754Sleep, Sleep Deprivation
Yuhui Qiu
Not applicable
60
Guangzhou
2025-08-08
Recruiting
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
NCT06892093HER2-positive Breast Cancer, Diarrhea Caused by Drug, Neratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
308
Guangzhou
2025-08-07
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study of AK146D1 for Injection in Advanced Solid Tumors
NCT07067567Advanced Solid Tumors
Akeso
Phase 1
200
Guangzhou
2025-08-07
Recruiting
Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
NCT07098351Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch
Guangdong Provincial People's Hospital
Not applicable
93
Guangzhou
2025-08-07
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
NCT07029451Infertility
Ferring Pharmaceuticals
Observational
2,500
Hefei, Maโ€™anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning
2025-08-05
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Rows per page Showing 901–1000 of 3318
Previous 8 9 10 11 12 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=10

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.